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Abstract
Background: Desferrioxamine (DFO) is an important iron chelating agent. It has also been
thought of as an agent with anti-oxidant potential as it chelates ferric iron in various parts of the
body. However, there is evidence suggesting that it may paradoxically affect red blood cells (RBC)
by inducing intracellular oxidant stress. To further understand the mechanism of DFO's interaction
with RBC, we conducted a study to determine the effect of DFO upon RBC's redox status.
Methods: We examined NAD redox potential in intact RBC (N = 5) incubated with DFO. RBC
were incubated with 6 mM DFO for 2 hours.
Results: Significant decreases in NAD redox potential were observed after incubation of RBC with
6 mM DFO. The mean decrease was 10.01  1.98% (p < 0.0004).
Conclusions: The data confirm the oxidant effect of DFO on RBC.
Introduction
Desferrioxamine (DFO) currently is the only iron chelator
that is available for clinical use in the United States. It is a
potent chelator that was originally obtained from an iron-
bearing metabolite of Actinomyceles (Streptomyces pilo-
sus) with specificity for ferric iron (Fe3+)[1,2]. Its stability
constant of 1031 for ferric iron contrasts significantly with
those for other ions such as zinc (1011), calcium (102)
and magnesium (104)[2]. Studies have demonstrated the
ability of DFO to remove iron from various iron pools in-
cluding ferritin and hemosiderin in iron-overloaded pa-
tients. DFO also competes with unsaturated transferrin
and removes non-transferrin bound iron [3].
DFO has also become known as an anti-oxidant. It is well
recognized that iron-mediated oxidant stress leads to lipid
peroxidation of the cell membrane and other cellular or
tissue damage[4,5]. Iron excess can occur at the tissue or
cell level with or without generalized iron overload as
seen with redox cycling compounds that can liberate iron
from ferritin [5]. Therefore, lipid peroxidation can occur
without generalized iron overload [6]. It is thought that
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elimination of free iron by a chelating agent such as DFO
is vital in preserving the integrity of the cell membrane
with localized or generalized free iron excess.
The observation that DFO protects tissues from oxidant
stress has become an important and well-regarded factor
in understanding its molecular qualities. However, there
is another aspect of DFO that is not as well recognized. As
one looks closer at the nature of DFO, it becomes appar-
ent that it also acts as a prooxidant molecule. Studies of
the redox mechanism have demonstrated that DFO in-
creases iron dependent radical formation [7]. There are
also data supporting DFO as being the cause of damage to
tissues [2,7–12], including a report of DFO aggravating in-
flammation and exacerbating the toxicity of certain xeno-
biotics [2]. Therefore, on one hand, DFO may be an
effective scavenger of potentially oxidant substances in
certain parts of the body, but on the other hand, it may
also act as a prooxidant in other areas such as the intracel-
lular environment of red blood cells.
Previously, we have published the data demonstrating
that DFO conjugated with starch leads to decrease in NAD
redox potential[13]. As conjugation with starch makes
DFO practically impossible to penetrate into RBC, it sup-
ported a notion that the oxidant stress was exerted from
outside of RBC. In the study presented here, our data fur-
ther demonstrate the prooxidant nature of DFO. This cur-
rent data confirms previous studies and shows that DFO
by itself without conjugation with starch does exert oxi-
dant stress.
Methods
Materials
Spectrophotometric grade ethanol was purchased from
Aldrich Chemical Co. (Milwaukee, WI). Desferoxamine
Mesylate (Sigma, catalogue number D-9533), alcohol de-
hydrogenase, (Sigma, catalogue number A-3263) and all
other reagents were purchased from Sigma Chemical Co.
(St. Louis, MO).
Study subjects and blood samples
After proper consent, five normal healthy adults volun-
teered to participate in the study. Blood samples were ob-
tained by routine venipuncture using heparin-coated
tubes (15 u heparin/ml whole blood) to prevent coagula-
tion.
DFO incubation and pyridine nucleotide extraction
Freshly drawn heparinized whole blood (425 l) was in-
cubated in a 37C water bath with DFO in saline buffer.
The final volume of the incubation sample was 500 l
with final concentrations of DFO at 0 mM and 6 mM.
Samples were collected at 2 hours of incubation and ex-
tracts were prepared immediately. Twenty l of incuba-
tion sample were mixed with 1,980 l of a solution
containing 10 mM nicotinamide, 20 mM NaHCO3, and
100 mM Na2CO3 at 0C. The mixture was frozen in a dry
ice-acetone bath for 20 minutes, then thawed quickly in a
room temperature water bath, and promptly chilled to
0C. To destroy the oxidized form of NAD, 700 l of this
mixture was incubated at 60C for 30 minutes. The mix-
ture was then chilled to 0C for 1 minute. Both the heat-
treated extract that contained NADH and the unheated ex-
tract that contained both the reduced and oxidized forms
of NAD were immediately analyzed using spectrophoto-
metric cycling assays [14].
NADH and total NAD assays
NAD was assayed using spectrophotometric enzymatic cy-
cling assays that measure both the oxidized and reduced
forms of the nucleotide as previously described[14,15].
Statistical analysis
Paired t-test was used to evaluate the differences of NAD/
NADH ratio values with and without DFO incubation.
Results
We evaluated blood samples from five normal volunteers.
There were consistent decreases in NAD redox potential
with 6 mM DFO-starch at 2-hour incubations. Mean de-
crease was 10.01  1.98% (p < 0.0004) (Table 1).
Figure. 1 illustrates the change in NAD redox potential of
each sample with DFO incubation.
Discussion
In this study, we demonstrated a decrease in NAD redox
potential in normal RBC by incubation with DFO, al-
though we must note that the in vitiro concentration DFO
Table 1: Net change of NADH/NAD ratio (%) in blood samples incubated 2 hours with DFO
DFO concentration Net Change p
NADH/NAD 0 mM 6 mM 0 mM – 6 mM
Ratio (%) 75.89  14.01 65.88  12.19 10.01  1.98 p < 0.0004
n = 5 DFO, DesferrioxamineBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/8
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used for the assay here is significantly higher than what is
expected with usual dosage used in clinical practice.
Nonetheless, as the NAD system comprises the major fac-
tor in intracellular antioxidant activity within the RBC,
this observation suggests the prooxidant effect of DFO
upon the cytosol of RBC[16]. In regard to the mechanism
of the prooxidant effect, because DFO is poorly permeable
to RBC membrane [3], the action of DFO may primarily
originate extracellularly to cause changes in the intracellu-
lar NAD redox potential. In fact, this concept of extracel-
lular oxidant stress was confirmed in previously published
data using DFO conjugated with starch to increase the
molecular weight [13]. With conjugation with starch, it
becomes impossible for the DFO to enter into RBC. There-
fore the oxidant stress, if present, must come from outside
of RBC yet it affects NAD which is inside the RBC. The
data presented here is to make certain that DFO by itself
without conjugation with starch leads to a decrease in
NAD redox potential.
There is a report of potential prooxidant effect of iron sat-
urated DFO solution [2]. Thus, one may consider the pos-
sibility of iron saturated DFO rather than DFO alone to be
the source of oxidant stress. It is possible that there is a
small fraction of iron bound DFO in the assay that may
exert oxidant stress. However, in our experiment, there is
no iron added to the solution. Therefore, although it is
speculative, with the amount of DFO used in the assay, it
is practically impossible for DFO to have scavenged mem-
brane iron and become saturated. In addition, because
RBC samples are from normal volunteers without any
known disease processes, it is very unlikely that there is a
significant amount of excess iron.
Several mechanisms may be considered to explain the ef-
fect of DFO on cytosol NAD redox potential. A potential
mechanism is that extracellular DFO is causing an in-
crease in ferric iron in RBC. It has been suggested for dec-
ades that the reaction between ferrous ion and DFO
involves oxidation of iron to the ferric state prior to com-
plexation [1]. Previous reports have demonstrated that
under oxygen-free conditions, there is no spectrophoto-
metric evidence (200–760 mu) for the formation of a
complex between ferrous sulfate and DFO. When the mix-
ture of iron and DFO was subsequently exposed to air or
oxygen, it led to the formation of a ferric complex [1].
These experimental results lend support to the notion that
DFO is likely to be involved in the conversion of ferrous
into ferric iron before the formation of complexes.
As these data imply that DFO induces conversion of fer-
rous to ferric iron prior to the formation of DFO-iron
complex [1], one may hypothesize that DFO may exert its
oxidant effect on iron without coming in contact with the
iron. Furthermore, DFO is perhaps able to oxidize iron
that is on the other side of the RBC membrane. As a con-
sequence, DFO removes membrane ferric iron, yet at the
same time, it may oxidize cytosol ferrous iron into ferric
iron. In this manner, DFO may behave as an antioxidant
as well as a prooxidant. A way to test this hypothesis may
be to study any change in methemoglobin level and cy-
tosol iron state before and after incubation with DFO.
There are reports that lipid peroxidation can be stimulated
by both free and complexed iron [17,18]. It is well docu-
mented that iron has an important role in oxidation and
inflammatory process. However, at the same time the evi-
dence shows that DFO with or without iron also appears
to contribute in the oxidation process [10,19–21]. Also,
there are other clinical data demonstrating that iron-free
DFO, rather than iron complexed DFO, can be the culprit
for toxicity [7,19]. Borg and Shariah have suggested that
DFO itself would exert prooxidant action by producing
highly reactive and potentially cytotoxic hydroxy radicals
[19]. Subsequently, electron spin resonance (ESR) spec-
troscopy studies have detected and identified a DFO ni-
troxide free radical generated by the reactions with UV
radiation [20], superoxide [10,21], and hydroxy radicals.
According to studies by Mordente et al., in air-saturated
solution, DFO appears to mediate one electron transfer
from ascorbate to oxygen, with generation of superoxide
anions leading to production of desferal nitroxide radicals
or the Fenton reaction: Fe2+ + H2O2  OH + Fe3+ + OH7.
The data presented in this paper concur with those reports
suggesting prooxidant activities of DFO. This does not
necessarily contradict the conventional wisdom of DFO as
an anti-oxidant in various aspects of biological systems.
However, it does provide an additional perspective that
allows us to better understand the potential effects and
Figure 1
NADH/NAD ratio (%) from blood samples incubated 2
hours with DFO.
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toxicity of the compound, which is essential for the appro-
priate application of this product.
DFO therapy has become a vital part in the management
of patients who require chronic transfusion therapy. Un-
less a better agent becomes available, DFO will continue
to be "the chelator" for these patients. Fortunately, DFO
has been the most effective and relatively safe iron chela-
tor for patients with transfusional iron overload. Howev-
er, as this medication is usually used on a chronic basis for
the patients, we need to continue to gather data on the
long term effects which may be attributable to DFO. In ad-
dition, since large numbers of patients who require iron
chelation therapy are those with RBC that are more sus-
ceptible to oxidant stress (i.e., sickle cell disease, tha-
lassemia), a clear understanding of the redox effect of
DFO cannot be over emphasized.
Conclusions
We observed a decrease in NAD redox potential of normal
RBC when incubated with DFO. This suggests a prooxi-
dant activity of DFO upon the intracellular environment
of RBC. Prooxidant activity of DFO is less well known and
reported compared to its antioxidant activity. However,
the evidence for prooxidant activity of DFO has been firm-
ly demonstrated previously, both with iron saturated and
unsaturated DFO. The factors affecting DFO to exert
prooxidant activity or antioxidant activities appear to
vary. Therefore, the two-sided observation of this single
molecule does not necessarily indicate a contradiction of
one from the other. In fact, they may complement each
other. Clinically, because DFO is used in large numbers of
patients, we need further understanding of the com-
pound. This is particularly true in patients with oxidant
susceptible RBC such as in sickle cell anemia and tha-
lassemia.
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